Treatment of dementia

Neurology in Practice

Volumn 76, Issue SUPPL. 5, 2005, Pages

  Overshott, Ross ^a   Burns, A ^a  

^a WYTHENSHAWE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; ESTROGEN; GALANTAMINE; GINKGO BILOBA EXTRACT; MEMANTINE; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; PROMAZINE; RISPERIDONE; RIVASTIGMINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

ABDOMINAL PAIN; AGGRESSION; AGITATION; ALTERNATIVE MEDICINE; ANOREXIA; APATHY; CLINICAL TRIAL; COGNITIVE DEFECT; COST EFFECTIVENESS ANALYSIS; DEMENTIA; DEPRESSION; DIAGNOSTIC ACCURACY; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG USE; EARLY DIAGNOSIS; EXCITABILITY; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEALTH CARE ACCESS; HUMAN; HYPEREXCITATION; MEMORY DISORDER; MINI MENTAL STATE EXAMINATION; NAUSEA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSIS; PSYCHOTHERAPY; QUALITY OF LIFE; RESTLESSNESS; REVIEW; SAFETY; SIDE EFFECT; STOMACH PAIN; STROKE; SYMPTOM; TREMOR; VEIN THROMBOSIS; VOMITING; WEIGHT REDUCTION;

AGED; BEHAVIOR; CHOLINESTERASE INHIBITORS; DEMENTIA; DRUG THERAPY, COMBINATION; HUMANS; PSYCHOMOTOR AGITATION; PSYCHOTIC DISORDERS;

EID: 28344456113     PISSN: 14737086     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2005.082537     Document Type: Review

References (29)

1. Rosen WG, Mohs RC, Davies KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-64.
2. Stern RG, Mohns RC, Davidson M, et al. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 1994;151:390-8.
3. Birks JS, Harvey R. Donepezil for dementia due to Alzheimer's disease. The Cochrane Database of Systematic Reviews 2003, issue 3.
4. Loy C, Schneider L. Galantamine for Alzheimer's disease. The Cochrane Database of Systematic Reviews 2003, issue 4.
5. Birks J, Grimley Evans J, lakovidou V, et al. Rivastigmine for Alzheimer's disease. The Cochrane Database of Systematic Reviews 2000, issue 4.
6. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's disease cooperative study - clinical global impression of change. The Alzheimer's disease cooperative study. Alzheimer Dis Assoc Disord 1997;11(suppl 2):S22-32.
7. Kaduszkiewicz H, Zimmerman T, Beck-Bornholdt H-P, et al. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ 2005;331:321-7.
8. National Institute for Health and Clinical Excellence. Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease. London: NICE, 2001, htttp://www.nice.org.uk/page.aspx?0= 14400.
9. National Institute for Health and Clinical Excellence. Appraisal consultation document: donepezil, rivastigmine, galantamine and memantine for the treatment of Alzheimer's disease. London: NICE, 2005, http:/www.nice.org.uk/ page.aspx70 = 245908.
10. Sana M, Wilcock GK, van Baelen B, et al. The effects of galantamine treatment on caregiver time in Alzheimer's disease. Int J Geriatr Psychiatry 2003;18:942-50.
11. Grimley Evans J, Wilcock G, Birke J. Evidence-based pharmacotherapy of Alzheimer's disease. Int J Neuropsychopharmacol 2004;7:351-69.
12. Auriacombe S, Pere JJ, Loria-Kanza Y, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who to benefit from treatment with donezepil. Com Med Res Opin 2002;18:129-38.
13. McKeith I, Del Sen T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomized, double-blind, placebo controlled international study, Lancet 2000;356:2031-6.
14. Erkinjuntti T, Roman G, Gauthier S, et al. Emerging therapies for vascular dementia and vascular cognitive impairment. Stroke 2004;35:1010-17.
15. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351:2509-18.
16. Potyk D. Treatments for Alzheimer disease. Southern Medical Association 2005;98:628-35.
17. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer's disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291:317-24.
18. Kurz A, Van Baelen B. Ginkgo biloba compared with cholinesterase inhibitors in the treatment of dementia: a review based on meta-analysis by the Cochrane Collaboration. Dement Geriatr Cogn Disord 2004;18:217-26.
19. Tariot PN, Federoff HJ. Current treatment for Alzheimer disease and future prospects. Alzheimer Dis Assoc Disord 2003;17:5105-13.
20. Wilcock G K, Birks J, Whitehead A, et al. The effect of selegiline in the treatment of people with Alzheimer's disease: a meta-analysis of published trials. Int J Geriatr Psychiatry 2002;17:175-83.
21. Sana M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopheroal or both as a treatment for Alzheimer's disease. The Alzheimer's disease cooperative study. N Engl J Med 1997;336:1216-22.
22. Bollard C, Cream J. Drugs used to reduce behavioural symptoms in people with dementia or an unacceptable chemical cost? Argument. Int Psychogeriatr 2004;17:4-12.
23. Overshott R, Byrne J, Burns A. Non-pharmacological and pharmacological interventions for symptoms in Alzheimer's disease. Expert Rev Neurotherapeutics 2004;4:809-21.
24. De Deyn PP, Katz IR, Brodaty H, et al. Management of agitation, aggression and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone. Clin Neurol Neurosurg 2005;107:497-508.
25. Department of Health. Public Health Link CEM/CMO/2004/1. Antipsychotics and Stroke. London: Department of Health, 2004, http://199.228.212.132/doh/ embroadcast.nsf/.
26. Hermann N, Mamdani KM, Lanctot KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatrists 2004;16:1113-15.
27. Teri L, Logsdon RG, Uomotu J, et al. Behavioural treatment of depression in dementia patients: a controlled clinical trial. J Gerontal B Pschol Sci Soc Sci 1997;52:159-66.
28. James I, Powell I, Kendell K. A cognitive perspective on training in care homes. Journal of Dementia Care 2003;11:22-4.
29. Cohen-Mansfield J. Non-pharmacological interventions for psychotic symptoms in dementia. J Geriatr Psychiatry Neurol 2003;16:219-24.